MSD secures EC clearance for Keytruda combination therapy for ovarian cancer

The approval also covers Keytruda SC, known in the US as Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph).

Merck granted EU approval of Keytruda combo in ovarian cancer

Merck (MRK) announced on Thursday that the European Commission approved its anti-PD-1 therapy Keytruda in combination with chemotherapy (paclitaxel) as a late-line option for certain adults with ...

Merck makes a big move into new cancer treatments with a $6.7 billion buyout deal

Merck to spend $6.7 billion to buy Terns Pharmaceuticals, which is developing an oral treatment for leukemia.

Adagene Drug Shows Stronger Tumor Response at Higher Dose in Early Cancer Trial

Adagene said early clinical trial results showed that its experimental cancer drug, muzastotug, worked better at higher doses when combined with Merck's Keytruda.